CrossRef

Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy

Journal of Interferon & Cytokine Research 36(3) (2016)

Gamal Eldeen Esmat; Wafa Al Akel; Rasha Ahmed Abdel Aziz; Ahmed Al Sayed Taha; Dina Sabry; Laila A. Rashed; Aya Mostafa; Amany Y. El Kazaz; Sahar H. Ahmed

Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt

PLOS ONE 12(10) (2017)

Ahmed Nagaty; Ekram W. Abd El-Wahab; Tatsuo Kanda

Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens

Journal of Interferon & Cytokine Research 38(3) (2018)

Maissa El-Raziky; Marwa Khairy; Ahmed Fouad; Ahmed Salama; Aisha Elsharkawy; Omnia Tantawy

Serum MicroRNAs as predictors for fibrosis progression and response to direct‐acting antivirals treatment in hepatitis C virus genotype‐4 Egyptian patients

International Journal of Clinical Practice 75(4) (2021)

Rasha M. M. Khairy; Safaa Said Hmmad; Mohamed Sayed; Hazem A. Ahmed; Mona Abdel Monem Esmail

Hepatitis C genotype 4: The past, present, and future

World Journal of Hepatology 7(28) (2015)

Tawhida Y Abdel-Ghaffar

A hepcidin homolog from Lateolabrax japonicus inhibits the infection of Anguillid herpesvirus 1 by interacting with the viral envelope protein ORF51

Virulence 17(1) (2026)

Yingyi Duan; Jun-Qing Ge; Xin-Zhan Meng; Fangyi Chen; Ke-Jian Wang

ENNAVIA is a novel method which employs neural networks for antiviral and anti-coronavirus activity prediction for therapeutic peptides

Briefings in Bioinformatics 22(6) (2021)

Patrick Brendan Timmons; Chandralal M Hewage

The effect of the degree of hepatitis C-related fibrosis on the responsiveness to pegylated interferon α-2a versus pegylated interferon α-2b

Egyptian Liver Journal 6(2) (2016)

Yehia M. El Shazly; Mohamed Abdel Hamid El Bokl; Mohamed Abdel Moghny Mostafa; Nanees A. Adel; Mohamed O. Khalifa; Ossama A. Ahmed; Ahmed I. El Shafie; Mohamed H.A. Fouad; Gina G. Naguib

Serum IL-12p70 and TLR 7 gene expression in Egyptian patients infected with HCV and treated with Sofosbuvir, Ribavirin and/or Pegylated interferon

International Journal of Biosciences (IJB) (2017)

Hala M. Aldesouki, Hanan M. Zidan, Eman M. Elashry

The current and future disease burden of chronic hepatitis C virus infection in Egypt

Arab Journal of Gastroenterology 15(2) (2014)

Imam Waked; Waheed Doss; Manal Hamdy El-Sayed; Chris Estes; Homie Razavi; Gamal Shiha; Ayman Yosry; Gamal Esmat

Pathology Predictors of Response to Combined Therapy of Chronic HCV Patients; Is it Applicable in the DAA Era?

Gastroenterology & Hepatology: Open Access 5(8) (2016)

Samar Kamal Darweesh

Effect of sofosbuvir and ribavirin therapy on hearing

The Scientific Journal of Al-Azhar Medical Faculty, Girls 4(3) (2020)

Naema Ismail; Gamal El-Serafy; Amal Ewida; Iman Eladawy; Mona Abd-Elmo′men

The Efficacy of aHansenula-Derived 20 kDa Pegylated Interferon Alpha-2a in the Treatment of Genotype 4 Chronic Hepatitis C

Journal of Interferon & Cytokine Research 34(9) (2014)

Hany Shehab; Tamer Elbaz; Dalia Deraz; Amal Hafez; Inas Elattar

Forecasted impacts of a sofosbuvir-based national hepatitis C treatment programme on Egypt’s hepatocellular cancer epidemic: simulation of alternatives

BMJ Global Health 3(2) (2018)

Wenkang Ma; Amr S Soliman; Wagida A Anwar; Ahmed Hablas; Tamer B El Din; Mohamed Ramadan; Ibrahim A Seifeldin; Mark L Wilson

Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4‐infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir

Journal of Viral Hepatitis 25(9) (2018)

G. Schnell; R. Tripathi; J. Beyer; T. Reisch; P. Krishnan; T. Dekhtyar; M. Irvin; C. Hall; Y. Yu; N. Mobashery; R. Redman; T. Pilot‐Matias; C. Collins

Meta-analysis

European Journal of Gastroenterology & Hepatology 26(11) (2014)

Brittany E. Yee; Nghia H. Nguyen; Bing Zhang; Philip Vutien; Carrie R. Wong; Glen A. Lutchman; Mindie H. Nguyen

Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations

World Journal of Gastroenterology 24(38) (2018)

Dalia Omran; Mohamed Alboraie; Rania A Zayed; Mohamed-Naguib Wifi; Mervat Naguib; Mohamed Eltabbakh; Mohamed Abdellah; Ahmed Fouad Sherief; Sahar Maklad; Heba Hamdy Eldemellawy; Omar Khalid Saad; Doaa Mohamed Khamiss; Mohamed El Kassas

Factors Affecting the Virological Response Among Chronic Hepatitis C Virus Patients in Yemen

Journal of Interferon & Cytokine Research 38(1) (2018)

Zaid Mutahar Mohammed Alezzi; Ayman Yosry Abd El Rehim; Waleed Fouad Fathallah; Mansour Ali Alamrani; Fouad Hezam Othman

Antiviral peptides as promising therapeutic drugs

Cellular and Molecular Life Sciences 76(18) (2019)

Liana Costa Pereira Vilas Boas; Marcelo Lattarulo Campos; Rhayfa Lorrayne Araujo Berlanda; Natan de Carvalho Neves; Octávio Luiz Franco

Untitled

Antiviral peptidlerin SARS COV-2 ana proteaz yapısına bağlanma etkinliklerinin protein-yanaştırma yöntemi ile incelenmesi: In silico bir çalışma

Frontiers in Life Sciences and Related Technologies 3(3) (2022)

İlter DEMİRHAN; Erkan ÖNER; Ergul BELGE KURUTAS

Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center

Current Medical Research and Opinion 38(4) (2022)

Mohamed El Kassas; Mohamed Eltabbakh; Mohamed Elbadry; Ahmed Tawheed; Tamer Elbaz

Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt

Expert Review of Anti-infective Therapy 18(7) (2020)

Gamal Esmat; Tamer Elbaz; Aisha Elsharkawy; Mohamed Abdullah; Mohamed El Kassas

HCV in Egypt, prevention, treatment and key barriers to elimination

Expert Review of Anti-infective Therapy 16(4) (2018)

Mohamed El Kassas; Tamer Elbaz; Aisha Elsharkawy; Heba Omar; Gamal Esmat

National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care

Journal of Viral Hepatitis 24(4) (2017)

W. El‐Akel; M. H. El‐Sayed; M. El Kassas; M. El‐Serafy; M. Khairy; K. Elsaeed; K. Kabil; M. Hassany; A. Shawky; A. Yosry; M. K. Shaker; Y. ElShazly; I. Waked; G. Esmat; W. Doss

Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study

The Egyptian Journal of Internal Medicine 34(1) (2022)

Radwa Samir Hagag; Morkoss Medhat Fakhry; Ossama Ashraf Ahmed; Shaimaa Abdalaleem Abdalgeleel; Mahasen Aly Radwan; Gina Gamal Naguib

Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C

Cochrane Database of Systematic Reviews 2014(2) (2014)

Goran Hauser; Tahany Awad; Kristian Thorlund; Davor Štimac; Mahasen Mabrouk; Christian Gluud

Optimal Management of HCV Genotype 4

Current Hepatology Reports 13(4) (2014)

Wael Abdel-Razek; Imam Waked

Optimizing treatment for HCV genotype 4: PEG‐IFN alfa 2a vs. PEG‐IFN alfa 2b; the debate continues

Liver International 34(s1) (2014)

Gamal Esmat; Mohamed El Kassas; Mohamed Hassany; Mohamed Gamil; Maissa El Raziky

Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis

BMJ Open Gastroenterology 2(1) (2015)

Brittany E Yee; Nghia H Nguyen; Bing Zhang; Derek Lin; Philip Vutien; Carrie R Wong; Glen A Lutchman; Mindie H Nguyen

Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C

Hepatitis Monthly 15(9) (2015)

Mahdiyar Pouresmaeeli; Seyed Moayed Alavian; Maryam Keshvari; Shima Salimi; Leila Mehrnoush

Untitled

Metabolic changes in chronic hepatitis C patients receiving direct acting antivirals

F1000Research 11 (2022)

Nehal K. Abdel Fattah; Sara M. Shaheen; Osama A. Ahmed; Kadry Elsaeed; Nagwa A. Sabri

The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting

VirusDisease 32(3) (2021)

Gina Gamal Naguib; Tari George Michael; Yehia Elshazly; Maha Magdy Wahdan; Aya Mostafa; Ossama Ashraf Ahmed; Hany Dabbous; Heba Ismail Saad Aly; Mohamed Kamal Shaker; Hosam Samir Elbaz; Magdy El-Serafy; Wahid Doss; Sherief Abd-Elsalam; Manal Hamdy El-Sayed

Management of hepatitis C genotype 4 in the directly acting antivirals era

BMJ Open Gastroenterology 3(1) (2016)

Emma Hathorn; Ahmed M Elsharkawy

A Real Life Study on Treatment of Egyptian Patients with HCV Genotype IV with Simeprevir and Sofosbuvir

Health 08(09) (2016)

A. Hanno; D. Elwazzan; M. Ibrahim; R. Hafez

Genotype 4 hepatitis C virus-a review of a diverse genotype

Advances in Medical Sciences 68(1) (2023)

Michał Brzdęk; Krystyna Dobrowolska; Robert Flisiak; Dorota Zarębska-Michaluk

Frequency of Sustained Virologic Response in Hepatitis C Positive, Treatment Naïve Patients on Sofosbuvir and Daclatasvir

Journal of Gandhara Medical and Dental Science 10(3) (2023)

Islam Shah; Nayab Munib; Aliena Badshah; Wazir Mohammad